Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal of the National Cancer Institute·2026
Same author

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

International journal of cancer·2026

Related Experiment Video

Updated: Jan 5, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.5K

[Chimeric antigen receptor T-cell therapy].

Klaus Müller1, Marianne Ifversen, Katrine Kielsen

  • 1kgmuller@gmail.com.

Ugeskrift for Laeger
|October 16, 2019
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell therapy offers a promising new treatment for relapsed or refractory hematological cancers. This approach genetically modifies a patient's T-cells to target cancer cells, with generally transient side effects.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

Related Experiment Videos

Last Updated: Jan 5, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Hematological cancer treatment has advanced, but outcomes for relapsed or refractory cases remain poor.
  • Chimeric antigen receptor (CAR) T-cell therapy represents a novel and promising therapeutic strategy.

Purpose of the Study:

  • To review the principles and emerging applications of CAR T-cell therapy in hematological malignancies.
  • To highlight the potential of CAR T-cell therapy as a treatment option for patients with poor prognoses.

Main Methods:

  • Review of current literature on CAR T-cell therapy.
  • Description of the mechanism of CAR T-cell function.
  • Discussion of clinical applications and outcomes.

Main Results:

  • CAR T-cell therapy involves genetically modifying a patient's T-cells to recognize and attack cancer cells.
  • Potential side effects associated with CAR T-cell therapy are typically transient.
  • A CD19 CAR T-cell product is now approved for acute lymphoblastic leukemia in Denmark, with in-house production underway.

Conclusions:

  • CAR T-cell therapy is a significant advancement in treating hematological cancers, offering hope for patients with refractory or relapsed disease.
  • The establishment of CAR T-cell production facilities will likely expand access to this innovative treatment.